Biosimilar Firms Say Irish Price Deal Hinders Uptake, As Govt Plans New Policy Measures
Executive Summary
The Irish health ministry is planning measures to boost the prescribing of biosimilar medicines, but companies marketing biosimilars say that the pricing agreement signed last year by the originator industry and the government has served to hinder uptake of their products.
You may also be interested in...
Irish Health Minister Speaks About EMA Relocation, Drug Pricing, and Boosting Biosimilars
Dublin will “absolutely” meet the criteria for hosting the European Medicines Agency, says Irish health minister Simon Harris. The minister has also outlined his department’s approach to high drug pricing and says he expects a national biosimilars policy by the end of the year.
Irish Health Minister Speaks About EMA Relocation, Drug Pricing, and Boosting Biosimilars
Dublin will “absolutely” meet the criteria for hosting the European Medicines Agency, says Irish health minister Simon Harris. The minister has also outlined his department’s approach to high drug pricing and says he expects a national biosimilars policy by the end of the year.
New Irish Generics Body Wants “Fundamental” Reform Of Medicines Procurement
Two generic industry associations have merged to form a single body that includes the largest generic companies in Ireland. Medicines For Ireland has marked its creation by saying it plans to push for a reform of Irish medicines procurement policies, particularly in areas such as tackling drug shortages, and has called for action to promote the use of biosimilars.